OTC Pharmaceuticals in Switzerland
Published: August 2013 · Publisher: MarketLine
OTC Pharmaceuticals in Switzerland industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017).
- Description
- Companies Mentioned
- Table of Contents
- Ask a Question
Introduction
OTC Pharmaceuticals in Switzerland industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Switzerland otc pharmaceuticals market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2012 annual average exchange rates.
*The Swiss OTC pharmaceuticals market had total revenues of $1,298.7m in 2012, representing a compound annual growth rate (CAGR) of 1.7% between 2008 and 2012.
*The cough and cold preparations segment was the market's most lucrative in 2012, with total revenues of $305.2m, equivalent to 23.5% of the market's overall value.
*The performance of the market is forecast to follow the similar pattern with an anticipated CARC of 1.6% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $1,402.6m by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the otc pharmaceuticals market in Switzerland
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the otc pharmaceuticals market in Switzerland
Leading company profiles reveal details of key otc pharmaceuticals market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Switzerland otc pharmaceuticals market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the Switzerland economy
Key Questions Answered
What was the size of the Switzerland otc pharmaceuticals market by value in 2012?
What will be the size of the Switzerland otc pharmaceuticals market in 2017?
What factors are affecting the strength of competition in the Switzerland otc pharmaceuticals market?
How has the market performed over the last five years?
Who are the top competitiors in Switzerland's otc pharmaceuticals market?
OTC Pharmaceuticals in Switzerland industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Switzerland otc pharmaceuticals market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2012 annual average exchange rates.
*The Swiss OTC pharmaceuticals market had total revenues of $1,298.7m in 2012, representing a compound annual growth rate (CAGR) of 1.7% between 2008 and 2012.
*The cough and cold preparations segment was the market's most lucrative in 2012, with total revenues of $305.2m, equivalent to 23.5% of the market's overall value.
*The performance of the market is forecast to follow the similar pattern with an anticipated CARC of 1.6% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $1,402.6m by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the otc pharmaceuticals market in Switzerland
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the otc pharmaceuticals market in Switzerland
Leading company profiles reveal details of key otc pharmaceuticals market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Switzerland otc pharmaceuticals market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the Switzerland economy
Key Questions Answered
What was the size of the Switzerland otc pharmaceuticals market by value in 2012?
What will be the size of the Switzerland otc pharmaceuticals market in 2017?
What factors are affecting the strength of competition in the Switzerland otc pharmaceuticals market?
How has the market performed over the last five years?
Who are the top competitiors in Switzerland's otc pharmaceuticals market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
Bayer AG, GlaxoSmithKline Plc, Johnson & Johnson and Novartis AG
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Market share 10
Market distribution 11
Market Outlook 12
Market value forecast 12
Five Forces Analysis 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
Bayer AG 19
GlaxoSmithKline Plc 23
Johnson & Johnson 27
Novartis AG 30
Macroeconomic Indicators 34
Country Data 34
Appendix 36
Methodology 36
Industry associations 37
Related research 37
LIST OF TABLES
Table 1: Switzerland OTC pharmaceuticals market value: $ million, 2008–12 8
Table 2: Switzerland OTC pharmaceuticals market category segmentation: $ million, 2012 9
Table 3: Switzerland OTC pharmaceuticals market share: % share, by value, 2012 10
Table 4: Switzerland OTC pharmaceuticals market distribution: % share, by value, 2012 11
Table 5: Switzerland OTC pharmaceuticals market value forecast: $ million, 2012–17 12
Table 6: Bayer AG: key facts 19
Table 7: Bayer AG: key financials ($) 20
Table 8: Bayer AG: key financials (€) 20
Table 9: Bayer AG: key financial ratios 21
Table 10: GlaxoSmithKline Plc: key facts 23
Table 11: GlaxoSmithKline Plc: key financials ($) 24
Table 12: GlaxoSmithKline Plc: key financials (£) 25
Table 13: GlaxoSmithKline Plc: key financial ratios 25
Table 14: Johnson & Johnson: key facts 27
Table 15: Johnson & Johnson: key financials ($) 28
Table 16: Johnson & Johnson: key financial ratios 28
Table 17: Novartis AG: key facts 30
Table 18: Novartis AG: key financials ($) 31
Table 19: Novartis AG: key financial ratios 32
Table 20: Switzerland size of population (million), 2008–12 34
Table 21: Switzerland gdp (constant 2000 prices, $ billion), 2008–12 34
Table 22: Switzerland gdp (current prices, $ billion), 2008–12 34
Table 23: Switzerland inflation, 2008–12 35
Table 24: Switzerland consumer price index (absolute), 2008–12 35
Table 25: Switzerland exchange rate, 2008–12 35
LIST OF FIGURES
Figure 1: Switzerland OTC pharmaceuticals market value: $ million, 2008–12 8
Figure 2: Switzerland OTC pharmaceuticals market category segmentation: % share, by value, 2012 9
Figure 3: Switzerland OTC pharmaceuticals market share: % share, by value, 2012 10
Figure 4: Switzerland OTC pharmaceuticals market distribution: % share, by value, 2012 11
Figure 5: Switzerland OTC pharmaceuticals market value forecast: $ million, 2012–17 12
Figure 6: Forces driving competition in the OTC pharmaceuticals market in Switzerland, 2012 13
Figure 7: Drivers of buyer power in the OTC pharmaceuticals market in Switzerland, 2012 14
Figure 8: Drivers of supplier power in the OTC pharmaceuticals market in Switzerland, 2012 15
Figure 9: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Switzerland, 2012 16
Figure 10: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Switzerland, 2012 17
Figure 11: Drivers of degree of rivalry in the OTC pharmaceuticals market in Switzerland, 2012 18
Figure 12: Bayer AG: revenues & profitability 21
Figure 13: Bayer AG: assets & liabilities 22
Figure 14: GlaxoSmithKline Plc: revenues & profitability 25
Figure 15: GlaxoSmithKline Plc: assets & liabilities 26
Figure 16: Johnson & Johnson: revenues & profitability 28
Figure 17: Johnson & Johnson: assets & liabilities 29
Figure 18: Novartis AG: revenues & profitability 32
Figure 19: Novartis AG: assets & liabilities 33
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Market share 10
Market distribution 11
Market Outlook 12
Market value forecast 12
Five Forces Analysis 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
Bayer AG 19
GlaxoSmithKline Plc 23
Johnson & Johnson 27
Novartis AG 30
Macroeconomic Indicators 34
Country Data 34
Appendix 36
Methodology 36
Industry associations 37
Related research 37
LIST OF TABLES
Table 1: Switzerland OTC pharmaceuticals market value: $ million, 2008–12 8
Table 2: Switzerland OTC pharmaceuticals market category segmentation: $ million, 2012 9
Table 3: Switzerland OTC pharmaceuticals market share: % share, by value, 2012 10
Table 4: Switzerland OTC pharmaceuticals market distribution: % share, by value, 2012 11
Table 5: Switzerland OTC pharmaceuticals market value forecast: $ million, 2012–17 12
Table 6: Bayer AG: key facts 19
Table 7: Bayer AG: key financials ($) 20
Table 8: Bayer AG: key financials (€) 20
Table 9: Bayer AG: key financial ratios 21
Table 10: GlaxoSmithKline Plc: key facts 23
Table 11: GlaxoSmithKline Plc: key financials ($) 24
Table 12: GlaxoSmithKline Plc: key financials (£) 25
Table 13: GlaxoSmithKline Plc: key financial ratios 25
Table 14: Johnson & Johnson: key facts 27
Table 15: Johnson & Johnson: key financials ($) 28
Table 16: Johnson & Johnson: key financial ratios 28
Table 17: Novartis AG: key facts 30
Table 18: Novartis AG: key financials ($) 31
Table 19: Novartis AG: key financial ratios 32
Table 20: Switzerland size of population (million), 2008–12 34
Table 21: Switzerland gdp (constant 2000 prices, $ billion), 2008–12 34
Table 22: Switzerland gdp (current prices, $ billion), 2008–12 34
Table 23: Switzerland inflation, 2008–12 35
Table 24: Switzerland consumer price index (absolute), 2008–12 35
Table 25: Switzerland exchange rate, 2008–12 35
LIST OF FIGURES
Figure 1: Switzerland OTC pharmaceuticals market value: $ million, 2008–12 8
Figure 2: Switzerland OTC pharmaceuticals market category segmentation: % share, by value, 2012 9
Figure 3: Switzerland OTC pharmaceuticals market share: % share, by value, 2012 10
Figure 4: Switzerland OTC pharmaceuticals market distribution: % share, by value, 2012 11
Figure 5: Switzerland OTC pharmaceuticals market value forecast: $ million, 2012–17 12
Figure 6: Forces driving competition in the OTC pharmaceuticals market in Switzerland, 2012 13
Figure 7: Drivers of buyer power in the OTC pharmaceuticals market in Switzerland, 2012 14
Figure 8: Drivers of supplier power in the OTC pharmaceuticals market in Switzerland, 2012 15
Figure 9: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Switzerland, 2012 16
Figure 10: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Switzerland, 2012 17
Figure 11: Drivers of degree of rivalry in the OTC pharmaceuticals market in Switzerland, 2012 18
Figure 12: Bayer AG: revenues & profitability 21
Figure 13: Bayer AG: assets & liabilities 22
Figure 14: GlaxoSmithKline Plc: revenues & profitability 25
Figure 15: GlaxoSmithKline Plc: assets & liabilities 26
Figure 16: Johnson & Johnson: revenues & profitability 28
Figure 17: Johnson & Johnson: assets & liabilities 29
Figure 18: Novartis AG: revenues & profitability 32
Figure 19: Novartis AG: assets & liabilities 33
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.